Last reviewed · How we verify

NCT03302065

Phase I Randomised, Four-period Balanced Incomplete Block Design Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Four Test pMDI Products With One Reference Product

Completed Phase 1 Last updated 27 November 2024
What this trial tests

Phase 1 trial testing Tiotropium in Healthy in 38 participants. Completed in 1 January 2017.

Timeline
1 May 2016
Primary endpoint
1 September 2016
1 January 2017

Quick facts

Lead sponsorSolventum US LLC
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposebasic science
Enrollment38
Start date1 May 2016
Primary completion1 September 2016
Estimated completion1 January 2017

Drugs / interventions tested

Conditions studied

Sponsor

Solventum US LLC — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to compare the absorption of four different inhalation products with the reference product in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tiotropium

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Solventum US LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03302065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing